Peer-influenced content. Sources you trust. No registration required. This is HCN.
Epoch Health
The FDA’s Class II designation indicates that exposure or usage of ‘a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote.’
Cardiology November 11th 2025
MedCentral
Unacceptable levels of N-nitroso atomoxetine, a potential carcinogen, were found in multiple atomoxetine batches, according to the FDA.
Clinical Pharmacology April 1st 2025
GoodRx for Healthcare Professionals
The introduction of lisdexamfetamine, a generic for Vyvanse, initially showed promise in increasing access to ADHD treatment. However, it too has fallen into shortage, highlighting the ongoing challenges in meeting patient demand.
Family Medicine/General Practice September 3rd 2024
DIET & NUTRITION 
PATIENT EDUCATION 
OBESITY/WEIGHT MANAGEMENT 
EXERCISE/TRAINING 
LEGAL MATTERS 
GUIDELINES/RECOMMENDATIONS